{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:27:12Z","timestamp":1775820432890,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Atrial Fibrillation (AF) is a condition that is five times more likely to cause a stroke and necessitates anticoagulation medication. In this regard, rivaroxaban, which is a direct oral anticoagulant (DOAC), has emerged as an alternative to vitamin K agonists (VKAs). Nevertheless, its relative safety and effectiveness compared to VKAs were not well-studied. Thus, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to identify the safety and effectiveness of rivaroxaban among patients with AF. The study protocol was registered with PROSPERO (CRD420251059453), and large databases, such as PubMed, Embase, and Scopus, were searched since their inception till March 2025. Outcomes of interest were risk of stroke, myocardial infarction (MI), bleeding, and mortality. The pooled risk ratios (RR) of each outcome were computed using the RevMan random effect model with 95% confidence intervals (CI). In total, four RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200917,634) were included, out of which 56.4% of participants were taking rivaroxaban and 43.6% were taking VKAs. Rivaroxaban had a significant effect in reducing the risk of hemorrhagic stroke [RR: 0.59 (95% CI 0.37, 0.94),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03], systemic embolism [RR: 0.36 (95% CI 0.18, 0.71),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003], fatal [RR: 0.43 (95% CI 0.29, 0.65),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0] and intracranial bleeding [RR: 0.63 (95% CI 0.46, 0.86),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004] while also increasing the risk of death from cardiac causes. There were no significant differences between the cohorts as far as ischemic stroke, MI, Heart Failure hospitalization, mortality, and major and minor bleeding outcomes are concerned. Large-scale trials ought to be carried out to test its importance in enhancing major clinical results such as ischemic stroke, death, and major and minor hemorrhage in AF patients.\n                  <\/jats:p>","DOI":"10.1186\/s40001-026-04139-9","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:05:03Z","timestamp":1772622303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of rivaroxaban vs. vitamin K antagonists in patients with atrial fibrillation: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"31","author":[{"given":"Muhammad Shaheer Bin","family":"Faheem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamikha","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Tawassul","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Takreem","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumaya","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"6","key":"4139_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ehjqcco\/qcaa061","volume":"7","author":"H Dai","year":"2021","unstructured":"Dai H, Zhang Q, Much AA, Maor E, Segev A, Beinart R, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574\u201382. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaa061.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"14","key":"4139_CR2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/2047487317715769","volume":"24","author":"V Ruddox","year":"2017","unstructured":"Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555\u201366. https:\/\/doi.org\/10.1177\/2047487317715769.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"4139_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4070\/kcj.2014.44.5.281","volume":"44","author":"K Senoo","year":"2014","unstructured":"Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014;44(5):281\u201390. https:\/\/doi.org\/10.4070\/kcj.2014.44.5.281.","journal-title":"Korean Circ J"},{"issue":"1","key":"4139_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","volume":"83","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109\u2013279. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.017.","journal-title":"J Am Coll Cardiol"},{"key":"4139_CR5","unstructured":"Asundexian inferior to apixaban for stroke prevention in atrial fibrillation. https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/Asundexian-inferior-to-apixaban-for-stroke-prevention-in-atrial-fibrillation. Accessed 11 Jun 2025."},{"issue":"3","key":"4139_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","volume":"83","author":"A Bejjani","year":"2024","unstructured":"Bejjani A, Khairani CD, Assi A, Piazza G, Sadeghipour P, Talasaz AH, et al. When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review. J Am Coll Cardiol. 2024;83(3):444\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"4139_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"key":"4139_CR8","doi-asserted-by":"publisher","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, A A Fox K, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Toda Kato E, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022 Jan 25;145(4):242\u2013255. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5. Erratum in: Circulation. 2022 Feb 22;145(8):e640.","DOI":"10.1161\/CIRCULATIONAHA.121.056355"},{"issue":"5","key":"4139_CR9","doi-asserted-by":"publisher","first-page":"e003206","DOI":"10.1161\/JAHA.116.003206","volume":"5","author":"LG Tereshchenko","year":"2016","unstructured":"Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis. J Am Heart Assoc. 2016;5(5):e003206. https:\/\/doi.org\/10.1161\/JAHA.116.003206.","journal-title":"J Am Heart Assoc"},{"key":"4139_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70003","author":"R Quir\u00f3s L\u00f3pez","year":"2025","unstructured":"Quir\u00f3s L\u00f3pez R, Formiga P\u00e9rez F, Beyer-Westendorf J. Adherence and persistence with direct oral anticoagulants by dose regimen: a systematic review. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70003.","journal-title":"Br J Clin Pharmacol"},{"key":"4139_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168531","author":"G Grze\u015bk","year":"2021","unstructured":"Grze\u015bk G, Rogowicz D, Wo\u0142owiec \u0141, Ratajczak A, Gilewski W, Chudzi\u0144ska M, et al. The clinical significance of drug-food interactions of direct oral anticoagulants. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22168531.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4139_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bcp.14404","volume":"87","author":"CSS Tan","year":"2021","unstructured":"Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol. 2021;87(2):352\u201374.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"4139_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2209051.","journal-title":"N Engl J Med"},{"key":"4139_CR14","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.5\u00a0(updated August 2024). Cochrane, 2024. www.training.cochrane.org\/handbook."},{"key":"4139_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4139_CR16","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4.1 The Cochrane Collaboration, 2020."},{"issue":"22","key":"4139_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2029603.","journal-title":"N Engl J Med"},{"issue":"1","key":"4139_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/ASN.2019060579","volume":"31","author":"AS De Vriese","year":"2020","unstructured":"De Vriese AS, Caluw\u00e9 R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study. J Am Soc Nephrol. 2020;31(1):186\u201396. https:\/\/doi.org\/10.1681\/ASN.2019060579.","journal-title":"J Am Soc Nephrol"},{"issue":"36","key":"4139_CR19","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314\u2013414.","journal-title":"Eur Heart J"},{"issue":"9921","key":"4139_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"4","key":"4139_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355.","journal-title":"Circulation"},{"key":"4139_CR22","doi-asserted-by":"publisher","first-page":"1125576","DOI":"10.3389\/fphar.2023.1125576","volume":"14","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, De Backer TL, Bertels X, Steurbaut S, Lahousse L. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study. Front Pharmacol. 2023;14:1125576.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4139_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40264-019-00842-1","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Durand M, Doyle CM, Yoon S, Reynier P, Filion KB. Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. Drug Saf. 2019;42(10):1135\u201348.","journal-title":"Drug Saf"},{"key":"4139_CR24","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. 2017. https:\/\/www.bmj.com\/content\/359\/bmj.j5058. Accessed 31 May 2025.","DOI":"10.1136\/bmj.j5058"},{"key":"4139_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.amjcard.2021.11.021","volume":"166","author":"MA Mamas","year":"2022","unstructured":"Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, et al. Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation. Am J Cardiol. 2022;166:58\u201364.","journal-title":"Am J Cardiol"},{"issue":"08","key":"4139_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH13-02-0150","volume":"110","author":"J Desai","year":"2013","unstructured":"Desai J, Kolb J, Weitz J, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants \u2013 defining the issues and the management strategies. Thromb Haemost. 2013;110(08):205\u201312.","journal-title":"Thromb Haemost"},{"key":"4139_CR27","doi-asserted-by":"crossref","unstructured":"Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population-based cohort study. 2015 Apr 24. https:\/\/www.bmj.com\/content\/350\/bmj.h1857. Accessed 31 May 2025.","DOI":"10.1136\/bmj.h1857"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04139-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:41:16Z","timestamp":1775817676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4139"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04139-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study does not involve direct data collection from human subjects or animals. All data used in this study were obtained from previously published and publicly available sources, adhering to the ethical guidelines of the respective studies. No identifiable patient information is presented in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}